Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

Zamagni, Elena; Oliva, Stefania; Gay, Francesca; Capra, Andréa; Rota–Scalabrini, Delia; D’Agostino, Mattia; Belotti, Angelo; Galli, Mónica; Racca, Manuela; Zambello, Renato; Gamberi, Barbara; Albano, Domenico; Bertamini, Luca; Versari, Annibale; Grasso, Mariella; Sgherza, Nicola; Priola, Claudia; Fioritoni, Francesca; Cicco, Gabriella De; Villanova, Tania; Pascarella, Anna; Zucchetta, Pietro; Tacchetti, Paola; Fanti, Stefano; Mancuso, Katia; Barbato, Simona; Boccadoro, Mario; Musto, Pellegrino; Cavo, Michèle; Nanni, Cristina

doi:10.1016/j.eclinm.2023.102017

Cited by 8 publications

(1 citation statement)

References 32 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging plays a key role in MRD evaluation, mainly PET/CT, whose prognostic value has been demonstrated in several studies [ 70 , 71 ]. Recently, using the Deauville scores (DS) to define PET complete metabolic response (CMR) in patients enrolled in the Phase II FORTE trial, PET negativity was found to significantly affect PFS, although the best outcome was observed in patients achieving before maintenance both PET/CT CMR and NGF negativity at level 10 −5 [ 72 ]. Sustained WB-RI negativity also, according to MY-RADS criteria [ 73 ], predicted outcome, since patients on maintenance after ASCT who were imaging MRD negative at 1 year (RAC 1) had a significantly longer PFS (median 55.4 vs. 28.4 months; HR = 0.12; p < 0.0001) and OS (median NR vs. 63 months; HR = 0.13; p < 0.0007) compared with patients with residual disease on WB-MRA (RAC ≥ 2) [ 74 ].…”

Section: Disease Monitoring At the Time Of Increasingly Effective The...mentioning

confidence: 99%

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

Morè,

Corvatta,

Manieri

et al. 2024

Cancers

View full text Add to dashboard Cite

The outcome of multiple myeloma (MM) has significantly improved in the last few decades due to several factors such as new biological discoveries allowing to better stratify disease risk, development of more effective therapies and better management of side effects related to them. However, handling all these aspects requires an interdisciplinary approach involving multiple knowledge and collaboration of different specialists. The hematologist, faced with a patient with MM, must not only choose a treatment according to patient and disease characteristics but must also know when therapy needs to be started and how to monitor it during and after treatment. Moreover, he must deal not only with organ issues related to MM such as bone disease, renal failure or neurological disease but also with adverse events, often very serious, related to novel therapies, particularly new generation immunotherapies such as CAR T cell therapy and bispecific antibodies. In this review, we provide an overview on the newer MM diagnostic and monitoring strategies and on the main side effects of MM therapies, focusing on adverse events occurring during treatment with CAR T cells and bispecific antibodies.

show abstract

Section: Disease Monitoring At the Time Of Increasingly Effective The...mentioning

confidence: 99%

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

Morè,

Corvatta,

Manieri

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders

Nanni,

Deroose,

Balogova

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

We provide updated guidance and standards for the indication, acquisition, and interpretation of [18F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [18F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [18F]FDG PET/CT imaging in routine practice and future research.

show abstract

Symptomatic Myeloma

Rossi,

Cattabriga,

Bezzi

2024

PET Clinics

View full text Add to dashboard Cite

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

Cited by 8 publications

References 32 publications

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management

EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders

Symptomatic Myeloma

Contact Info

Product

Resources

About